内生增长+外延收购双轮驱动策略
Search documents
美丽田园医疗健康(02373.HK)2025 年业绩预告点评 内生外延驱动业绩提升,稳步释放龙头效应
Guolian Minsheng Securities· 2026-01-23 00:20
Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [3][13]. Core Insights - The company is expected to achieve a revenue of at least 3 billion RMB in 2025, representing a year-on-year growth of no less than 16%. Adjusted net profit is projected to be at least 380 million RMB, with a year-on-year increase of no less than 40% [9]. - The company's performance is driven by both organic growth and external expansion, with significant contributions from the acquisition of the second-ranked beauty brand, Nair, enhancing market share and profitability [9]. - The successful acquisition of Shanghai Siyuanli, a well-known brand in the high-end beauty service sector, is expected to further strengthen the company's market position and resource density [9]. - The integration of the top three brands in the industry is anticipated to continuously release the company's leading effect, promoting a "super brand, super chain, and super digitalization" strategy to reshape the beauty industry's value space [9]. Financial Projections - Revenue forecasts for 2025-2027 are 30.20 billion RMB, 39.86 billion RMB, and 45.84 billion RMB, with growth rates of 17.4%, 32.0%, and 15.0% respectively [3][11]. - Adjusted net profit is projected to be 3.85 billion RMB in 2025, 5.10 billion RMB in 2026, and 6.00 billion RMB in 2027, with year-on-year growth rates of 52.8%, 32.4%, and 17.6% respectively [3][11]. - The earnings per share (EPS) based on adjusted net profit is expected to be 1.53 RMB in 2025, 2.03 RMB in 2026, and 2.38 RMB in 2027, with corresponding price-to-earnings (P/E) ratios of 17, 13, and 11 [3][11].